Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Expenses (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Operating Expenses for 16 consecutive years, with $15.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 22.58% to $15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.3 million through Dec 2025, up 6.8% year-over-year, with the annual reading at $47.3 million for FY2025, 6.8% up from the prior year.
  • Operating Expenses hit $15.0 million in Q4 2025 for Cumberland Pharmaceuticals, up from $10.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $15.5 million in Q4 2023 to a low of $9.6 million in Q3 2021.
  • Historically, Operating Expenses has averaged $11.6 million across 5 years, with a median of $11.1 million in 2022.
  • Biggest five-year swings in Operating Expenses: soared 36.23% in 2023 and later dropped 20.95% in 2024.
  • Year by year, Operating Expenses stood at $12.7 million in 2021, then dropped by 10.04% to $11.4 million in 2022, then surged by 36.23% to $15.5 million in 2023, then decreased by 20.95% to $12.3 million in 2024, then rose by 22.58% to $15.0 million in 2025.
  • Business Quant data shows Operating Expenses for CPIX at $15.0 million in Q4 2025, $10.3 million in Q3 2025, and $11.6 million in Q2 2025.